NSAIDs activate PTEN and other phosphatases in human colon cancer cells: Novel mechanism for chemopreventive action of NSAIDs

Biochemical and Biophysical Research Communications

Volumn 320, Issue 3, 2004, Pages 875-879

  Chu, Eric C ^a   Chai, Jianyuan ^a   Tarnawski, Andrzej S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoprevention; Colon cancer; NSAIDs; PTEN

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATASE; PHOSPHOTYROSINE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BAD; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOPROPHYLAXIS; CHROMOSOME 10; CONTROLLED STUDY; DEPHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CACO-2 CELLS; CHEMOPREVENTION; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; NITROBENZENES; PHOSPHORIC MONOESTER HYDROLASES; PLATELET-DERIVED GROWTH FACTOR; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SULFONAMIDES; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEINS;

EID: 3042796486     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.06.036     Document Type: Article

References (44)

1. Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1991;1593-1596
2. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121:1994;241-246
3. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., Speizer F.E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:1995;609-614
4. Chan A.T., Giovannucci E.L., Schernhammer E.S., Colditz G.A., Hunter D.J., Willett W.C., Fuchs C.S. A prospective study of aspirin use and the risk for colorectal adenoma. Ann. Intern. Med. 140:2004;157-166
5. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1993;1313-1316
6. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:2000;1946-1952
7. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348:2003;891-899
8. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., Steinbach G., Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348:2003;883-890
9. Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., Parsons R., Tonks N.K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA. 94:1997;9052-9057
10. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 273:1998;13375-13378
11. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA. 95:1998;15587-15591
12. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA. 96:1999;4240-4245
13. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501
14. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362
15. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:1997;64-67
16. Nelen M.R., van Staveren W.C., Peeters E.A., Hassel M.B., Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.P., Sijmons R.H., Woods D.G., Mariman E.C., Padberg G.W., Kremer H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6:1997;1383-1387
17. Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L., Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.L., Bonnetblanc J.M., Bressieux J.M., Cabarrot-Moreau A., Chompret A., Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.P., Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Eng C., et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7:1998;507-515
18. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., Shiff S.I., Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:1996;237-245
19. Shureiqi I., Chen D., Lotan R., Yang P., Newman R.A., Fischer S.M., Lippman S.M. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 60:2000;6846-6850
20. Totzke G., Schulze-Osthoff K., Janicke R.U. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene. 22:2003;8021-8030
21. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947
22. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57:1997;4183-4186
23. Saito M., Okamoto A., Kohno T., Takakura S., Shinozaki H., Isonishi S., Yasuhara T., Yoshimura T., Ohtake Y., Ochiai K., Yokota J., Tanaka T. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int. J. Cancer. 85:2000;160-165
24. Teng D.H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K.L., Vinson V.L., Gumpper K.L., Ellis L., El-Naggar A., Frazier M., Jasser S., Langford L.A., Lee J., Mills G.B., Pershouse M.A., Pollack R.E., Tornos C., Troncoso P., Yung W.K., Fujii G., Berson A., Steck P.A., et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57:1997;5221-5225
25. Chen J., Lindblom P., Lindblom A. A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum. Genet. 102:1998;124-125
26. Risinger J.I., Hayes A.K., Berchuck A., Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57:1997;4736-4738
27. Yokoyama Y., Wan X., Shinohara A., Takahashi S., Takahashi Y., Niwa K., Tamaya T. Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int. J. Mol. Med. 6:2000;47-50
28. Salvesen H.B., MacDonald N., Ryan A., Jacobs I.J., Lynch E.D., Akslen L.A., Das S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer. 91:2001;22-26
29. Kawamura N., Nagai H., Bando K., Koyama M., Matsumoto S., Tajiri T., Onda M., Fujimoto J., Ueki T., Konishi N., Shiba T., Emi M. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn. J. Cancer Res. 90:1999;413-418
30. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57:1997;3660-3663
31. Celebi J.T., Shendrik I., Silvers D.N., Peacocke M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet. 37:2000;653-657
32. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57:1997;4997-5000
33. Alimov A., Li C., Gizatullin R., Fredriksson V., Sundelin B., Klein G., Zabarovsky E., Bergerheim U. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 19:1999;3841-3846
34. Forgacs E., Biesterveld E.J., Sekido Y., Fong K., Muneer S., Wistuba I.I., Milchgrub S., Brezinschek R., Virmani A., Gazdar A.F., Minna J.D. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 17:1998;1557-1565
35. Halachmi N., Halachmi S., Evron E., Cairns P., Okami K., Saji M., Westra W.H., Zeiger M.A., Jen J., Sidransky D. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer. 23:1998;239-243
36. Nakahara Y., Nagai H., Kinoshita T., Uchida T., Hatano S., Murate T., Saito H. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia. 12:1998;1277-1280
37. Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood. 92:1998;3410-3415
38. ′ -kinase activation by the protein tyrosine phosphatase Shp2 Mol. Cell. Biol. 22:2002;4062-4072
39. R. Huang, J. Chai, A.S. Tarnawski, Do NSAIDs activate apoptosis in human colon cancer cells? Identification of specific genes and pathways involved, Gastroenterology 124(Suppl. A) (2003) 239
40. Zhang T., Fields J.Z., Ehrlich S.M., Boman B.M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J. Pharmacol. Exp. Ther. 308:2004;434-437
41. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20:2000;5010-5018
42. Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276:2001;48627-48630
43. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276:2001;993-998
44. Li D.M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57:1997;2124-2129